Early Gastric Cancer Clinical Trial
— EPSILONOfficial title:
EndoscoPic Submucosal dIssection Using geL Versus glycerOl for Submucosal iNjection: a Randomized Controlled Multicentric Trial (EPSILON)
Verified date | October 2023 |
Source | Erasme University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The EPSILON study aims to comparatively evaluate the submucosal injection using ORISETM gel and glycerol during an ESD procedure in a specific population with superficial gastric and rectal (pre)neoplastic lesions.
Status | Terminated |
Enrollment | 32 |
Est. completion date | January 5, 2023 |
Est. primary completion date | December 15, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - o Patients must have given written informed consent - o Subjects with documented gastric or rectal lesions with indication of endoscopic removal by ESD, namely: - Gastric focal lesion with suspicion of early gastric cancer (low or high grade dysplasia with features of early gastric cancer; adenocarcinoma with morphology of superficial lesion and work-up of superficial lesion) - Rectal polyps (adenoma or superficial carcinoma) from 0 to 15 cm from the anal margin; with features being recognized indications of ESD: more than 20mm granular LST, more than 20mm non granular LST, more than 20mm villous or bulging polyps, Paris 0-IIa+IIc lesions, lesions with suspicious pattern (Kudo Vi / JNET 2B), lesions with anal canal involvement. Exclusion Criteria: - Subjects who meet any of the following exclusion criteria cannot be enrolled in the study: - Gastric and rectal neuroendocrine tumour (NET) with indication of ESD will be excluded - Gastric and rectal lesions with indication of ESD but strong fibrosis due to previous partial resection will be excluded - Subject is currently enrolled in another confounding research - Subjects with any other location of ESD (esophagus, duodenum and colon) will not be included. |
Country | Name | City | State |
---|---|---|---|
Belgium | Erasme Hospital, Université Libre de Bruxelles. (ULB) | Brussels | |
Germany | Evangelisches Krankenhaus | Düsseldorf | |
Japan | Keio University Hospital | Tokyo |
Lead Sponsor | Collaborator |
---|---|
Erasme University Hospital |
Belgium, Germany, Japan,
Cao Y, Liao C, Tan A, Gao Y, Mo Z, Gao F. Meta-analysis of endoscopic submucosal dissection versus endoscopic mucosal resection for tumors of the gastrointestinal tract. Endoscopy. 2009 Sep;41(9):751-7. doi: 10.1055/s-0029-1215053. Epub 2009 Aug 19. — View Citation
Castro R, Libanio D, Pita I, Dinis-Ribeiro M. Solutions for submucosal injection: What to choose and how to do it. World J Gastroenterol. 2019 Feb 21;25(7):777-788. doi: 10.3748/wjg.v25.i7.777. — View Citation
Endoscopic Classification Review Group. Update on the paris classification of superficial neoplastic lesions in the digestive tract. Endoscopy. 2005 Jun;37(6):570-8. doi: 10.1055/s-2005-861352. — View Citation
Fujishiro M, Yahagi N, Kashimura K, Mizushima Y, Oka M, Enomoto S, Kakushima N, Kobayashi K, Hashimoto T, Iguchi M, Shimizu Y, Ichinose M, Omata M. Comparison of various submucosal injection solutions for maintaining mucosal elevation during endoscopic mu — View Citation
Fujishiro M. Perspective on the practical indications of endoscopic submucosal dissection of gastrointestinal neoplasms. World J Gastroenterol. 2008 Jul 21;14(27):4289-95. doi: 10.3748/wjg.14.4289. — View Citation
Hewett DG, Kaltenbach T, Sano Y, Tanaka S, Saunders BP, Ponchon T, Soetikno R, Rex DK. Validation of a simple classification system for endoscopic diagnosis of small colorectal polyps using narrow-band imaging. Gastroenterology. 2012 Sep;143(3):599-607.e1 — View Citation
Kodashima S, Fujishiro M, Yahagi N, Kakushima N, Omata M. Endoscopic submucosal dissection using flexknife. J Clin Gastroenterol. 2006 May-Jun;40(5):378-84. doi: 10.1097/00004836-200605000-00004. — View Citation
Lian J, Chen S, Zhang Y, Qiu F. A meta-analysis of endoscopic submucosal dissection and EMR for early gastric cancer. Gastrointest Endosc. 2012 Oct;76(4):763-70. doi: 10.1016/j.gie.2012.06.014. Epub 2012 Aug 9. — View Citation
Park YM, Cho E, Kang HY, Kim JM. The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: a systematic review and metaanalysis. Surg Endosc. 2011 Aug;25(8):2666-77. doi: 10.1007/ — View Citation
Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T, Repici A, Vieth M, De Ceglie A, Amato A, Berr F, Bhandari P, Bialek A, Conio M, Haringsma J, Langner C, Meisner S, Messmann H, Morino M, Neuhaus H, Piessevaux H, Rugge M, Saunders BP, Robaszkiewicz M, Seewald — View Citation
Sano Y, Tanaka S, Kudo SE, Saito S, Matsuda T, Wada Y, Fujii T, Ikematsu H, Uraoka T, Kobayashi N, Nakamura H, Hotta K, Horimatsu T, Sakamoto N, Fu KI, Tsuruta O, Kawano H, Kashida H, Takeuchi Y, Machida H, Kusaka T, Yoshida N, Hirata I, Terai T, Yamano H — View Citation
Takezawa T, Hayashi Y, Shinozaki S, Sagara Y, Okada M, Kobayashi Y, Sakamoto H, Miura Y, Sunada K, Lefor AK, Yamamoto H. The pocket-creation method facilitates colonic endoscopic submucosal dissection (with video). Gastrointest Endosc. 2019 May;89(5):1045 — View Citation
Yamamoto H, Hayashi Y, Despott EJ. The pocket-creation method for endoscopic submucosal dissection combined with saline-immersion: another potential option to overcome challenges in colorectal endoscopic submucosal dissection. Gastrointest Endosc. 2019 Au — View Citation
* Note: There are 13 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Number of per-procedural bleeding | Number of per-procedural bleeding (+ severity scale: oozing / severe non pulsating/ severe pulsating) | At day 0 during ESD | |
Other | Total hemostatic time | Total hemostatic time (addition of each hemostasis time for each per-procedural bleeding) | At day 0 during ESD | |
Other | Need for haemostatic forceps | Need for haemostatic forceps during ESD | At day 0 during ESD | |
Other | Difficulty of the dissection | Difficulty of the dissection (scale) (very easy / easy / moderately difficult / difficult / very difficult) | At day 0 during ESD | |
Other | Amount of submucosal solution | Amount of submucosal solution (glycerol or gel) used for ESD in ml | At day 0 during ESD | |
Other | Combined use of saline | Combined use of saline through the knife during ESD (number and ml) | At day 0 during ESD | |
Other | Number of needle injection dots | Number of needle injection dots during ESD (initially / during ESD) | At day 0 during ESD | |
Other | Need to adjust electrosurgical settings | Need to adjust electrosurgical settings during ESD | At day 0 during ESD | |
Other | Clear visualisation of the plane of dissection during ESD (scale). | Clear visualisation of the plane of dissection during ESD (scale). The scale will be defined according the endoscopists evaluation of the delineation between the submucosa ad the underlying muscular layer:
Very-good visualization: clear delineation between the two layers with clear visualization of the blood vessels. Good visualization: mostly clear delineation between the two layers, but with blurred regions Bad visualization: delineation between the two layers is unclear (i.e.: fibrosis) |
At day 0 during ESD | |
Other | Rate of en-bloc dissection | Rate of en-bloc dissection (defined as endoscopic resection of the targeted area in one bloc) | At day 0 during ESD | |
Other | Rate of complete endoscopic resection | Rate of complete endoscopic resection (defined as endoscopic evaluation of complete removal of the targeted area in the treated organ) | At day 0 during ESD | |
Other | Quality assessment of the pathological specimen | Quality assessment of the pathological specimen (absolute measure of the depth of resected submucosa on the specimen, rate of clear (horizontal and vertical) margins) | At day 0 during ESD | |
Other | Adverse events | Adverse events:
Per-procedural (incidence of all adverse technical events during the procedure) Early (clinical and laboratory at 24 h post procedure according to CTCAE v 5.0) Late (clinical at 2-3 weeks follow-up) |
From ICF signature up to 2-3 weeks follow-up | |
Primary | Increase the dissection speed of the ESD procedure | Increase the dissection speed of the ESD procedure (defined as the dissected surface (mm2)/ESD duration (min). The dissected surface is defined as maximal diameter of specimen (mm) x perpendicular minimal diameter of specimen (mm) measured on ex-vivo pinned stretched specimen onto a cork. ESD duration is defined as the time from first submucosal injection to final cut time. | At day 0 during ESD | |
Secondary | Total procedure duration | Total procedure duration (from scope insertion to scope retrieval) (min) | At day 0 during ESD |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04083573 -
Comparison of Diagnostic Performance of Medical Monitor and Medical Augmented Reality Glasses in Endoscopy: Observation Study
|
||
Completed |
NCT02504164 -
Effect of Midazolam Premedication on the Satisfaction Levels of Patients After Endoscopic Submucosal Dissection
|
N/A | |
Recruiting |
NCT01774266 -
Detection of Methylated Reprimo in Plasma for Asymptomatic Gastric Cancer
|
N/A | |
Completed |
NCT01435525 -
Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation
|
N/A | |
Completed |
NCT01921283 -
Monitored Anesthesia Care With Propofol Plus Remifentanil During Endoscopic Submucosal Dissection: Evaluation of Bispectral Index Monitoring
|
N/A | |
Completed |
NCT01364324 -
Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients
|
||
Recruiting |
NCT03837301 -
Non-exposure Simple Suturing EFTR (NESS-EFTR) With Laparoscopic Sentinel Lymph Node Navigation for EGC (Senorita3-phase 2)
|
Phase 2 | |
Recruiting |
NCT05269056 -
Early Detection of Gastric Cancer Using Plasma Cell-free DNA Fragmentomics
|
||
Not yet recruiting |
NCT03632746 -
Verifying the Specificity of a New Method in Predicting Lymph Node Metastasis in Early Gastric Cancer Patients
|
||
Completed |
NCT01938326 -
Pure Single Incision Laparoscopic Distal Gastrectomy (SIDG) Versus Totally Laparoscopic Distal Gastrectomy (TLDG)
|
N/A | |
Recruiting |
NCT04602689 -
Fibrin Glue After ESD for High Risk Patients of Bleeding
|
N/A | |
Recruiting |
NCT05291728 -
Screening for Early Gastric Cancer in Shaanxi Province
|
||
Not yet recruiting |
NCT06152783 -
Confocal Laser Microendoscopy (CellTouch) for the Diagnosis of Early Gastric Cancer: A Multicenter Clinical Study
|
||
Completed |
NCT02189226 -
Usefulness of Probe-based Confocal Laser Endo-microscopy in Delineation of Margin of Early Gastric Cancer for Endoscopic Submucosal Dissection
|
N/A | |
Completed |
NCT04602299 -
Setting the Shortest Examination Time of Gastroscopy to Improve the Detection Rate of Upper Gastrointestinal Tumors
|
N/A | |
Completed |
NCT02562976 -
OLGA Stage is More Appropriate in Predicting Early Gastric Cancer
|
N/A | |
Recruiting |
NCT01132469 -
Efficacy and Safety Study of Endoscopic Submucosal Dissection for Early Gastric Cancer
|
N/A | |
Completed |
NCT03136354 -
Prospective Randomized Trial Comparing Endoscopic Submucosal Dissection Against Laparoscopic Assisted Gastrectomy for Treatment of Early Gastric Cancer
|
N/A | |
Completed |
NCT02216110 -
Endoscopic Submucosal Dissection Versus Gastrectomy
|
N/A | |
Recruiting |
NCT04411589 -
The Diagnostic Ability of White Light Endoscopy and Magnifying Endoscopy With Optical Enhancement System
|
N/A |